Form 4: Milestone Pharmaceuticals Director Seth Fischer Granted 40,000 Stock Options

Milestone Pharmaceuticals Inc. Director Seth H. Z. Fischer was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months or by the next annual meeting.

Summary

• Seth H. Z. Fischer, a Director of Milestone Pharmaceuticals Inc. (MIST), was granted 40,000 stock options.
• The transaction date for this grant was June 10, 2025.
• The exercise price for these stock options is $1.75 per share.
• The options will vest in twelve equal monthly installments, commencing on July 10, 2025.
• The options will be fully vested on the date of the next annual meeting of the stockholders of Milestone Pharmaceuticals Inc., provided the Reporting Person continues to provide service through each vesting date.
• The expiration date for these stock options is June 10, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard corporate governance practice that aligns the director's interests with shareholder value, indicating continued commitment to the company. It is not a significant market-moving event but is generally viewed as a positive for governance.

Positives

• The grant of stock options to Director Seth H. Z. Fischer aligns his interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice for retaining and motivating key board members.

Future Outlook

The vesting schedule indicates a future commitment from the director, with options vesting over 12 equal monthly installments starting July 10, 2025, or fully vesting by the next annual meeting, contingent on continued service.

Industry Context

The grant of stock options to a director is a common and standard practice within the biotechnology and pharmaceutical industries for executive and board compensation, aiming to align the interests of leadership with long-term shareholder value.

Comparison to Industry Standards

• Stock option grants are a widely accepted form of equity compensation for directors across various industries, including biotech, as they provide a performance-based incentive tied to the company's stock performance.
• The vesting schedule, which includes monthly installments and full vesting by the next annual meeting, is a typical structure designed to ensure continued service and commitment from the director.

Related Party Transactions

• The grant of stock options to Seth H. Z. Fischer, a Director of Milestone Pharmaceuticals Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Director (Seth H. Z. Fischer): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The Reporting Person must continue to provide service to Milestone Pharmaceuticals Inc. for the stock options to vest according to the schedule.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant